Abstract Background Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein. However. the majority of human sarcomas have normal level of MDM2 and the therapeutic... https://countryscenesaddleryandpetsuppliers.shop/product-category/hay-bag/